symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
TRVN,0.603,1.913751,820821,6614307,0,0.537-5.125,0.003,"Trevena, Inc.",USD,0001429560,US89532E1091,89532E109,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.trevena.com,"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.",Ms. Carrie L. Bourdow,Healthcare,US,35,610 354 8840,955 Chesterbrook Boulevard,Chesterbrook,PA,19087,2.03053,3.74053,https://financialmodelingprep.com/image-stock/TRVN.png,2014-01-31,False,False,True,False,False
